Davis-Ajami Mary Lynn, Wu Jun, Downton Katherine, Ludeman Emilie, Noxon Virginia
Organizational Systems and Adult Health, University of Maryland School of Nursing, Baltimore, MD, USA.
South Carolina College of Pharmacy, University of South Carolina, Greenville, SC, USA.
Biologics. 2014 Apr 16;8:155-67. doi: 10.2147/BTT.S27578. eCollection 2014.
Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat symptomatic anemia of renal origin in adult and pediatric patients on hemodialysis and adults on peritoneal dialysis, as well as for symptomatic renal anemia in adult patients with renal insufficiency not yet on dialysis. Currently, epoetin zeta can be administered either subcutaneously or intravenously to correct for hemoglobin concentrations ≤10 g/dL (6.2 mmol/L) or with dose adjustment to maintain hemoglobin levels at desired levels not in excess of 12 g/dL (7.5 mmol/L). This review article focuses on epoetin zeta indications in chronic kidney disease, its use in managing anemia of renal origin, and discusses its pharmacology and clinical utility.
促红细胞生成素ζ于2007年10月获得欧洲药品管理局的上市许可，作为一种重组人促红细胞生成素促红细胞生成剂，用于治疗接受血液透析的成人和儿童患者以及接受腹膜透析的成人患者的肾源性症状性贫血，以及尚未接受透析的肾功能不全成人患者的症状性肾性贫血。目前，促红细胞生成素ζ可通过皮下或静脉注射给药，以纠正血红蛋白浓度≤10 g/dL（6.2 mmol/L），或通过调整剂量将血红蛋白水平维持在不超过12 g/dL（7.5 mmol/L）的期望水平。这篇综述文章重点关注促红细胞生成素ζ在慢性肾脏病中的适应证、其在治疗肾源性贫血中的应用，并讨论其药理学和临床应用价值。
